Misplaced Pages

BMB-201

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Serotonergic drug

Pharmaceutical compound
BMB-201
Clinical data
Other namesBMB201; BMB-A39a prodrug
Drug classNon-hallucinogenic serotonin 5-HT2A and 5-HT2C receptor partial agonist

BMB-201 is a serotonin 5-HT2A and 5-HT2C receptor agonist described as a non-hallucinogenic psychoplastogen which is under development for the treatment of depression, anxiety, pain, and other indications.

The drug is a prodrug of another compound called BMB-A39a. It acts as a partial agonist of the serotonin 5-HT2A and 5-HT2C receptors. BMB-A39a is less efficacious in activating Gq signaling at the serotonin 5-HT2A and 5-HT2C receptors compared to psilocin (EmaxTooltip Maximal efficacy = 68% vs. 82% at 5-HT2A and 79% vs. 95% at 5-HT2C for BMB-201 and psilocin, respectively). The EC50Tooltip half-maximal effective concentration value of BMB-A39a in activating the serotonin 5-HT2C receptor is around 10-fold higher than for activating the 5-HT2A receptor (EC50 = 6.7 nM and 71.2 nM, respectively). In addition to the serotonin 5-HT2A and 5-HT2C receptors, BMB-A39a is a potent partial agonist of the serotonin 5-HT1F and 5-HT6 receptors. Conversely, BMB-A39a shows minimal or negligible activity in activating the serotonin 5-HT2B receptor (Emax < 20%) and does not activate other serotonin receptors.

BMB-201 is said to have minimal or absent psychedelic effects due to its reduced serotonin 5-HT2A receptor intrinsic activity but to potently induce neuroplasticity. It has been reported to show effectiveness in animal models of depression, anxiety, pain, and substance use disorder.

BMB-201 is under development by Bright Minds Biosciences. As of October 2024, its highest developmental phase is preclinical research. The chemical structure of BMB-201 does not yet appear to have been disclosed.

See also

References

  1. ^ "Delving into the Latest Updates on BMB-201 with Synapse". Synapse. 29 October 2024. Retrieved 30 October 2024.
  2. ^ "BMB-201 Drug Profile". Ozmosi. Retrieved 30 October 2024.
  3. ^ Vasilkevich A, Duan J, Lovera A, McCorvy J, Pedersen JT (October 2024). Novel 5-HT2A/2C mixed and partial agonist and its efficacy in preclinical pain models (PDF). Society for Neuroscience 2024 Annual Meeting, Chicago, October 5-9.
  4. ^ "Bright Minds Investor Deck" (PDF). Bright Minds Biosciences Inc. September 2024.
  5. "Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models". BioSpace. 17 October 2024. Retrieved 30 October 2024.

External links

Serotonin receptor modulators
5-HT1
5-HT1A
5-HT1B
5-HT1D
5-HT1E
5-HT1F
5-HT2
5-HT2A
5-HT2B
5-HT2C
5-HT37
5-HT3
5-HT4
5-HT5A
5-HT6
5-HT7
Categories: